Aurobindo Pharma announced a significant development today. Its subsidiary, CuraTeQ Biologics, has received a compliance notice from Health...

"Because data show these treatments are highly unlikely to be active against the omicron variant, which is circulating at a very high frequ...

The treatment contains antibodies, which are usually produced naturally in response to a COVID infection or vaccination. They work by recog...

The research enrolled nearly 1,400 patients, of whom 696 received the drug combo.

About 100 Covid-19 patients have so far undergone antibody cocktail treatment at various hospitals in the city with successful outcomes.

The company said the participants in the trial were unvaccinated adults older than 18 years with confirmed exposure to a person with the co...

The only Indian company Zydus Cadila which claims to have developed neutralising monoclonal antibodies (mAbs)-based cocktail for the treatm...

The Mohali-based Fortis Hospital, in a statement, said the patient, who had tested positive for the infection two days ago, is a diabetic w...

As part of this single dose infusion-based treatment, patients with mild to moderate symptoms, are offered a cocktail of Casirivimab and Im...

The WHO draft document, seen by Reuters and dated Oct. 30, says the priorities are to secure monoclonal antibodies in a tight market and to...

Lilly is also doing preclinical studies of a third antibody treatment for the illness caused by the new coronavirus that could enter human ...

More recently, scientists have developed treatments called monoclonal antibodies -- antibodies that can be isolated and manufactured in lar...

More research is needed to see whether the findings are confirmed in a clinical setting and how precisely the antibody defeats the virus.

RMAb has been developed by Pune-based Serum Institute of India (SII) and US-based Mass Biologics of the University of Massachusetts Medical...

Glenmark Pharmaceuticals S.A., a wholly owned Swiss subsidiary of Glenmark Pharmaceuticals, said GBR 830 is entering human trials.

Glenmark Pharmaceuticals opened a new manufacturing facility in Switzerland for supply of clinical trial material.

GBR 900 is a monoclonal antibody for the treatment of chronic pain targeting TrkA, the receptor of nerve growth factor (NGF).